According to a study, a novel medication called enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may promote clinical action against cancer across the body.
According to a study, a novel medication called enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may promote clinical action against cancer across the body.
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.
Washington, April 7: According to a study, a novel medication called enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may promote clinical action against cancer across the body.
Immunotherapy Agent Safe, Shows Promise Against High-Risk Prostate Cancers miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.